You are in: eMedicine Specialties > Pediatrics: General Medicine > Allergy and Immunology AspleniaArticle Last Updated: Aug 2, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Joseph C Turbyville, MD, Chief of Pediatrics, Department of Pediatrics, Evans Army Community Hospital/Medical Center Joseph C Turbyville is a member of the following medical societies: American Academy of Pediatrics Coauthor(s): Cecilia P Mikita, MD, MPH, Assistant Chief, Clinical Services, Walter Reed Army Medical Center Allergy-Immunology Clinic; Director, Y8 Immunology and Allergy Specialty Course; Mudra Kumar, MD, MBBS, MRCP, Associate Professor, Department of Pediatrics, University of South Florida College of Medicine; Francine Gross, MD, Consulting Staff, Department of Pediatrics, Winter Haven Hospital Editors: Ann O'Neill Shigeoka, MD †, Former Clinical Associate Professor, Department of Pediatrics, Division of Immunology-Rheumatology, University of Utah School of Medicine; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; John Wilson Georgitis, MD, Consulting Staff, Lafayette Allergy Services; David Pallares, MD, Clinical Assistant Professor, Department of Pediatrics, Division of Allergy and Immunology, University of Louisville; Mark Ballow, MD, Professor, Department of Pediatrics, State University of New York at Buffalo; Chief, Division of Allergy and Immunology, Women and Children's Hospital of Buffalo Author and Editor Disclosure Synonyms and related keywords: asplenia, hypoplasia, splenic hypoplasia, absent spleen, nonfunctional spleen, autosplenectomy, hyposplenia, splen, Ivemark syndrome, asplenia syndrome, functional asplenia, congenital asplenia INTRODUCTIONBackgroundAbsent or defective splenic function is associated with a high risk of fulminant bacterial infections, especially with encapsulated bacteria. Asplenia and splenic hypoplasia are terms used to indicate complete or partial lack of splenic function. Loss of splenic function usually occurs as a result of surgical removal or autosplenectomy, ie, infarction in patients with hemoglobinopathies. Congenital splenic anomalies are usually accompanied by abnormalities in other organ systems, especially cardiac abnormalities, but they may occur in isolation. Polysplenia, ie, bilateral left-sidedness, is also frequently associated with congenital cardiac anomalies. Patients with polysplenia have multiple spleens, and their splenic function is usually normal. Isolated asplenia or hyposplenia is often diagnosed only after the patient has had a serious, fulminant, and often fatal infection. These conditions are extremely difficult to diagnose in the absence of other indicators. Morphologic anomalies of peripheral blood erythrocytes, such as Howell-Jolly (HJ) bodies, may be the only evidence of the presence of a nonfunctional spleen (see Workup). PathophysiologyThe embryologic control of splenogenesis resides in the homeobox gene HOXD11. In humans, the spleen is the site for early hematopoietic development, particularly the development of erythrocytes during the first 4 months of gestation. After birth, the spleen has several important functions such as the provision of primary immunologic defensive responses. The spleen has an active role in phagocytosis and in the production of immunoglobulin M (IgM) antibodies and complement. It also plays a significant role in the functional maturation of antibodies. The spleen is a significant reservoir for T lymphocytes. The percentages of total T cells (CD3) and T helper cells (CD4) and the lymphoproliferative responses to mitogens (concanavalin A, phytohemagglutinin, pokeweed mitogen) may decrease in patients with asplenia. However, these T-cell changes reflect the loss of the spleen as a reservoir rather than a direct T-cell abnormality. The impaired clearance of opsonized particles, decreased IgM levels, and poor antibody production (especially in response to polysaccharide antigens) contribute to the increased susceptibility of these patients to serious and often fatal infections. Apart from this filtering and immunologic function, the spleen acts as an important scavenger. For example, the spleen participates in the destruction of all 3 blood elements: erythrocytes, white cells, and platelets. It also plays an important role in the selective removal of abnormal cells (spherocytes, poikilocytes) and intracellular inclusions (Heinz bodies, HJ bodies). These functions are known as culling and pitting, respectively, and are the basis of the hematologic abnormalities observed in patients with absent splenic function. The white pulp of the spleen contains germinal centers with B lymphocytes, plasma cells, and macrophages. The red pulp, composing the largest part of the spleen, consists of endothelial cords of Billroth and sinusoids. In the red pulp, erythrocytes are processed, and inclusions such as HJ bodies, Heinz bodies, and autophagic vacuoles are removed. Because the spleen is important in antibody synthesis and has a critical role in clearing bacteria from the bloodstream, a patient with asplenia is at significant risk for life-threatening infections and fulminant sepsis, especially in their first 2 years of life. In infants younger than 6 months, gram-negative enteric organisms such as Klebsiella species and Escherichia coli are the most common pathogens. After age 6 months, Streptococcus pneumoniae and Haemophilus influenzae type b may cause fulminant sepsis; Neisseria meningitidis is less common. Malaria, babesiosis, and certain viral infections may also be more severe in individuals with asplenia. The younger the patient at the time of splenic function loss, the higher his or her risk for serious infection. Asplenia is most often found in association with other anomalies. The most common of these anomalies is the Ivemark syndrome, which is also referred to as asplenia syndrome. Visceral heterotaxy is present with bilateral right-sidedness. The right-sided organs are duplicated, and organs that are normally present on the left side are absent. Infants with Ivemark syndrome usually present during the neonatal period with cyanosis and respiratory distress resulting from complex cardiac anomalies. Transposition of the great arteries with pulmonary stenosis (72%) or atresia (88%) and total anomalous venous drainage (72%) are common. Accompanying malformations may involve the gastrointestinal system secondary to aberrant mesenteric attachments and renal anomalies. The liver tends to be symmetrical and transverse, and the stomach may be in the midline and hypoplastic. This condition is more common in males than in females, and most patients (79%) die in their first year of life because of cardiovascular complications. A clue to the underlying problems may be obtained by carefully examining radiographs, which may reveal abnormal placement of the cardiac apex, stomach bubble, and liver. Other associated conditions include Pearson syndrome (pancreatic insufficiency, sideroblastic anemia), which is a mitochondrial disorder associated with splenic atrophy. Asplenia is also present in Stormorken syndrome (thrombocytopenia and miosis). Occasionally, asplenia may be present in Smith-Fineman-Myers syndrome (mental retardation, short stature, cryptorchidism) and ATR-X syndrome (a-thalassemia and mental retardation). Asplenia may be associated with caudal deficiency or cystic disease of the liver, kidney, and pancreas. It has also been reported in association with Fanconi aplastic anemia. Functional asplenia is associated with conditions such as sickle cell disease, hemoglobin SC disease, and sickle cell hemoglobin (Hb S) b-thalassemia. Most children with these hemoglobinopathies are functionally hyposplenic in the first year of life and anatomically asplenic (due to autoinfarction) by the second decade of life. The infection risks in these individuals parallel those of patients with asplenia. Patients who undergo splenectomy because of thalassemia or Hodgkin disease have a higher risk of overwhelming infection than those patients with functional hyposplenia secondary to sickle cell disease. Additional conditions associated with splenic hypofunction include neonatal age, rheumatologic diseases (systemic lupus erythematous [SLE], rheumatoid arthritis), inflammatory bowel disease, graft versus host disease, and nephrotic syndrome. Patients may also have traumatic injuries to the spleen and require surgical splenectomy. Congenital anomalies of the spleen may be isolated, but most cases of asplenia or polysplenia result from interference in the establishment of normal right-left symmetry during embryogenesis (laterality sequences). Asplenia may be viewed as bilateral right-sidedness, of which Ivemark syndrome is an example. Asplenia is associated with dextrocardia in approximately one third of the cases. Congenital cardiac anomalies are more frequent and often more severe in asplenia than in polysplenia. Polysplenia may be regarded as bilateral left-sidedness, and it may be associated with left atrial isomerism. Vascular disturbances, including failure of the splenic artery to reach the developing spleen, may be a possible explanation for isolated asplenia. Familial situs abnormalities may be related to chromosome band Xq24-q27.1. Splenic hypoplasia is a poorly defined and infrequently recognized condition. It is usually not associated with other anomalies and may be familial. Asplenia or polysplenia may be associated with significant abnormalities of the cardiovascular system, with occasional involvement of the pulmonary, gastrointestinal, and genitourinary systems. The cardiac abnormalities are generally complex and include endocardial cushion defects, pulmonary atresia or stenosis, transposition of the great vessels, total anomalous pulmonary venous return, and a double-outlet right ventricle. Similar cardiac defects may be present in both polysplenia and asplenia. However, cyanotic heart diseases, including severe atrioventricular canal defects, tend to be more common in asplenia, whereas acyanotic defects, which usually occur with increased pulmonary blood flow, are more common in polysplenia. In polysplenia, the stomach may be on the right side, and multiple spleens are found along the greater curvature. Absence of the hepatic portion of the inferior vena cava with an azygous venous connection is characteristic. Data regarding splenic competency in polysplenia are scarce. Reports vary from suboptimal function to normal function. Accessory spleens should be distinguished from polysplenia. In polysplenia, a normal spleen with multisystem involvement is absent. Accessory spleens are usually located in the hilus of the normal spleen or in the tail of the pancreas. The accessory splenules are typically small and clinically insignificant, but they may become hypertrophied in certain situations. FrequencyUnited StatesThe exact incidence of these conditions is not known. Asplenia or polysplenia is present in approximately 3% of neonates with structural heart disease and in 30% of patients who die from cardiac malposition. Isolated asplenia or hyposplenia is probably an underdiagnosed condition that is most often recognized at autopsy. Mortality/Morbidity
Sex
AgeThe risk of bacteremia is higher in younger children compared with older children. CLINICALHistoryAll patients with congenital or acquired asplenia or splenic dysfunctional are at significant risk of fulminant bacteremia, especially from encapsulated bacteria. S pneumoniae is the most common pathogen implicated in bacteremia in these patients. Other encapsulated organisms include H influenzae type b, N meningitidis, E coli, Staphylococcus aureus, and other streptococci. Gram-negative bacilli including Salmonella species, Klebsiella species, and Pseudomonas aeruginosa are less common causes of bacteremia in patients with asplenia. These patients are also at risk for malaria and babesiosis.
Physical
Causes
DIFFERENTIALS
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Penicillin V (V-Cillin K, Veetids) |
|---|---|
| Description | Bactericidal b-lactam antibacterial antibiotic. Main activity is against gram-positive organisms such as streptococci, some gram-negative organisms, and anaerobes. Approximately 60% of oral dose is absorbed. Best taken on empty stomach. Some prefer amoxicillin because it is more bioavailable and less expensive. Preferred for children <2 y. Oral susp (125 or 250 mg/mL) available. |
| Adult Dose | 250 mg PO bid |
| Pediatric Dose | <5 years: 125 mg PO bid >5 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase effectiveness by decreasing clearance; tetracyclines are bacteriostatic, decreasing effectiveness when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Caution in renal impairment; rash commonly observed; anaphylactic shock, erythema nodosum, and interstitial nephritis less common; possible cross-reactivity with cephalosporin allergy |
| Drug Name | Erythromycin (EES, E-Mycin, Eryc) |
|---|---|
| Description | Used for those with penicillin hypersensitivity. Limited activity against H influenzae. Bacteriostatic antibiotic that acts mainly by inhibiting protein synthesis. Administer >1-2 h pc. Oral susp, chewable tab, and enteric-coated tab available. |
| Adult Dose | 250 mg PO bid |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; hepatic impairment |
| Interactions | Inhibits CYP3A4 isoenzymes and decreases terfenadine, cisapride, and astemizole clearance, which may result in serious cardiac arrhythmias; may also increase toxicity of theophylline, digoxin, carbamazepine, triazolam, midazolam, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin increases risk of rhabdomyolysis |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Caution in liver disease; estolate formulation may cause cholestatic jaundice; GI adverse effects common (give doses pc); discontinue if nausea, vomiting, malaise, abdominal colic, or fever occur |
| Drug Name | Amoxicillin (Amoxil, Trimox) |
|---|---|
| Description | Superior bioavailability and stability to gastric acid and has broader spectrum of activity than penicillin. Somewhat less active than that of penicillin against Streptococcus pneumococcus. Penicillin-resistant strains also resistant to amoxicillin, but higher doses may be effective. More effective against gram-negative organisms (eg, N meningitidis, H influenzae) than penicillin, thus may provide better prophylaxis in children <2 y. Susp (125, 200, 250, or 400 mg/5 mL) and pediatric drops (50 mg/mL) available. |
| Adult Dose | 250 mg PO bid |
| Pediatric Dose | <5 years: 125 mg PO bid >5 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | May reduce effectiveness of oral contraceptives; probenecid increases serum concentration |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Caution in cephalosporin allergy; dose adjustments may be necessary in renal failure; carefully evaluate rash to differentiate nonallergic ampicillin rash from hypersensitivity reaction |
Active immunization increases resistance to infection. Vaccines consist of microorganisms or cellular components that act as antigens. The administration of the vaccine stimulates the production of antibodies with specific protective properties.
Given the increased problem of penicillin resistance in S pneumoniae, prevention by using PCV7 in children or by using PPV23 in children and adults is mandatory. Similarly, immunizations with the conjugated H influenzae type b vaccine and the meningococcal conjugated or polysaccharide vaccine are essential.
| Drug Name | Pneumococcal 7-valent conjugate vaccine (Prevnar) |
|---|---|
| Description | Sterile solution of saccharides of capsular antigens of S pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F individually conjugated to diphtheria CRM197 protein. These 7 serotypes responsible for >80% of invasive pneumococcal disease in children <6 y in the United States. Accounts for 74% of penicillin-nonsusceptible S pneumoniae (PNSP) and 100% of pneumococci with high-level penicillin resistance. First dose recommended at age 2 mo, but it can be given in patient as young as 6 wk. Preferred sites of IM injection are the anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in toddlers and young children. Do not inject in gluteal area or areas where a major nerve trunk or blood vessel may be present. Three 0.5-mL doses for infants aged 7-11 mo (4 wk apart; third dose after first birthday), 2 doses for 12-23 mo (2 mo apart), 1 dose for >24 mo through 9 y. Minor illnesses such as a mild upper respiratory tract infection with or without low-grade feverare generally not contraindications. |
| Adult Dose | Not established |
| Pediatric Dose | 3 doses of 0.5 mL each at >2-mo intervals, followed by a fourth dose of 0.5 mL at age 12-15 mo; recommended dosing interval is 4-8 wk; administer fourth dose 2 mo or longer after third dose |
| Contraindications | Documented hypersensitivity; severe or moderate febrile illness; infants or children with thrombocytopenia or coagulation disorder contraindicating IM injection (unless benefits outweigh risks) |
| Interactions | Effects may decrease with immunosuppressive agents (immunosuppressive doses of corticosteroids, antimetabolites, alkylating agents, cytotoxic agents); may increase effects of anticoagulant therapy; globulin preparations may interfere with immune response and reduce effectiveness (do not administer within 3 mo of vaccine) |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | For IM use only, do not administer IV under any circumstances; take special care to prevent injection into or near a blood vessel or nerve; caution in patients with possible history of latex sensitivity (packaging contains dry natural rubber); does not replace 23-valent pneumococcal polysaccharide vaccination in children >24 mo with sickle cell disease, asplenia, HIV infection, chronic illness, or immunocompromise; caution in coagulation disorders |
| Drug Name | Pneumococcal vaccine (Pneumovax-23, Pnu-Imune 23) |
|---|---|
| Description | Polyvalent vaccine used for prophylaxis against infection with S pneumoniae. Used in populations with increased risk for pneumococcal pneumonia (eg, >55 y, chronic infection, asplenia, immunocompromise). |
| Adult Dose | 0.5 mL IM/SC once |
| Pediatric Dose | <2 years: Contraindicated (antibody response poor in this age group) >2 years: 0.5 mL IM/SC; repeat dose after 3-5 y in high-risk children (eg, those with functional or anatomic asplenia, those with conditions associated with rapid antibody decline after initial vaccination) |
| Contraindications | Documented hypersensitivity to any component; severe or even a moderate febrile illness; age <2 y; thrombocytopenia or any coagulation disorder contraindicating IM injection unless potential benefits clearly outweigh risks |
| Interactions | Immunosuppressive agents (large amounts of corticosteroids, antimetabolites, alkylating agents, cytotoxic agents) may reduce effectiveness; therapy with immunoglobulin preparations likely to block active immunity induced with pneumococcal vaccination, withhold for 3 mo after discontinuation of immunoglobulin therapy |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | May cause arthralgia, fever, urticaria, Guillain-Barré syndrome (rare) |
| Drug Name | Haemophilus influenzae type b vaccines (Comvax, HibTITER, ActHIB) |
|---|---|
| Description | For routine immunization of children against invasive diseases caused by H influenzae type b. Decreases nasopharyngeal colonization. The CDC Advisory Committee on Immunization Practices (ACIP) recommends that all children routinely receive one of the conjugate vaccines licensed for use in infants beginning at age 2 mo. |
| Adult Dose | Not indicated |
| Pediatric Dose | Regimens vary depending on product; one example for HibTITER follows. 2-6 months: 0.5 mL IM q2mo for 3 doses 7-11 months: If previously unvaccinated, 0.5 mL IM q2mo for 2 doses 12-14 months: If previously unvaccinated, 0.5 mL IM once Booster dose: All children, 0.5 mL at age 15 mo or at least 2 mo after last dose of series; if aged 15-71 mo and previously unvaccinated, 0.5 mL IM given only once |
| Contraindications | Documented hypersensitivity |
| Interactions | Corticosteroids or cyclosporine may inhibit full immunologic response |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Delay immunization if febrile illness evident; may cause erythema, swelling, or tenderness; cause-effect relationship with observed postvaccination Guillain-Barré syndrome not established |
| Drug Name | Meningococcal vaccine (Menomune) |
|---|---|
| Description | Capsular polysaccharide antigens (groups A, C, Y, and W-135) of N meningitidis. Used for active immunization against invasive meningococcal disease caused by inclusive serogroups. May be used to prevent and control outbreaks of serogroup C meningococcal disease according to CDC guidelines. Routine vaccination is recommended for high-risk groups (eg, deficiencies in late complement components [C3, C5-C-9], functional or actual asplenia, laboratory or industrial exposure to N meningitidis aerosols, travelers or residents of hyperendemic areas). The vaccine induces antibody response for serogroup A in individuals as young as 3 mo, but it is poorly immunogenic for serogroup C in recipients who are younger than 18-24 mo. For information concerning geographic areas in which vaccination is recommended, contact the CDC at (404)-332-4559. |
| Adult Dose | 0.5 mL SC |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; avoid during course of acute illness |
| Interactions | Coadministration with whole-cell pertussis or whole-cell typhoid vaccines may increase endotoxin content; immunosuppressive drugs may interfere with immune response |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Deficiencies in late complement components (C3, C5-C9); do not administer IV/IM/ID; functional or actual asplenia; persons with laboratory or industrial exposure to N meningitidis aerosols; travelers to and residents of hyperendemic areas such as sub-Saharan Africa |
| Drug Name | Meningococcal conjugate vaccine (Menactra) |
|---|---|
| Description | Capsular polysaccharide antigens (groups A, C, Y, and W-135) of N meningitidis individually conjugated to diphtheria toxoid proteins. Used for active immunization in adolescents and adults aged 11-55 years for the prevention of invasive meningococcal disease caused by inclusive serogroups. Routine vaccination also recommended for high-risk groups (eg, those with deficiencies in late complement components [C3, C5-C-9], functional or anatomic asplenia, properdin deficiencies, and travelers or residents of hyperendemic areas). In 2005, 5 reports of Guillain-Barré Syndrome were described following Menactra administration. Whether these cases were caused by the vaccine or were coincidental is unknown. The FDA and CDC are actively investigating the situation because of its potentially serious nature. |
| Adult Dose | <55 years: 0.5 mL IM once |
| Pediatric Dose | >11 years: Administer as in adults |
| Contraindications | Known hypersensitivity to vaccine component or natural rubber latex; patients with bleeding disorder or patients on anticoagulant therapy |
| Interactions | Administration of immunoglobulin within 1 mo or concurrent administration with immunosuppressive agents may inhibit full immunologic response; coadministration with whole-cell pertussis or whole-cell typhoid vaccines may increase endotoxin content |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Risks include hemorrhage, local pain, headache, or fatigue |
| Drug Name | Influenza virus vaccine |
|---|---|
| Description | Indicated for active immunization to prevent influenza a and b viruses. Induces antibodies following administration specific to virus strains contained in vaccine. Influenza vaccine contents are determined annually by the US Public Health Service. Typically, 3 live, attenuated virus strains are included in the formulation each year, which antigenically represent the influenza strains likely to circulate the next flu season. |
| Adult Dose | 0.5 mL IM for 1 dose each year prior to flu season |
| Pediatric Dose | <6 months: Not established 6-35 months: 0.25 mL IM once; administer second dose 4 wk after first dose for vaccine-naïve children 3-8 years: 0.5 mL IM once; administer second dose 4 wk after first dose for vaccine-naïve children >8 years: 0.5 mL IM for 1 dose each year prior to flu season Fluviron: <4 years: Not established Fluarix: <18 years: Not established |
| Contraindications | Documented hypersensitivity to vaccine contents including thimerosal, eggs, egg products, or chicken protein; history of Guillain-Barré syndrome; history of neurologic symptoms following vaccination |
| Interactions | Immunosuppressive therapy (eg, high-dose corticosteroids, chemotherapy) may reduce antibody response |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Defer vaccination with acute febrile illnesses or neurological findings until symptoms have abated; may cause soreness at injection site, fever, malaise, and myalgia |
| Media file 1: Peripheral blood smear shows Howell-Jolly (HJ) bodies in RBCs. | |
![]() | View Full Size Image | Media type: Photo |
Article Last Updated: Aug 2, 2006